Belgian drug discovery company Galapagos NV (GLPG.BT) said Wednesday it has expanded its arthritis alliance with GlaxoSmithKline (GSK) to include additional drug discovery programs based on novel drug target GT622.

Under the deepened alliance, Galapagos will receive a payment from GSK of EUR6.5 million cash and becomes eligible for additional success-based milestones and royalties. Since the start of the alliance in June 2006, Galapagos has received a total of EUR41 million in payments from GSK.

MAIN FACTS:

-The expanded arthritis alliance with GSK is now worth more than 200 million in milestones, plus up to double-digit royalties, the company said.

-By Brussels Bureau, Dow Jones Newswires; +322 741 1480;
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Galapagos Charts.
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Galapagos Charts.